Increasing Cases Of Chronic Diseases Is Propelling The Global Bone Marrow Transplant Market

Triton Market Research presents the Global Bone Marrow Transplant Market report segmented by Transplant type (Autologous Bone Marrow transplant, Allogeneic Bone Marrow Transplant), by Indication (Multiple myelomas, Acute leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, Solid tumors, Other indication), by End user (Multispecialty clinics, Hospitals, Ambulatory surgical centers), by Geographical Region (North America, Europe, Asia Pacific and Rest of World), discussing Industry Value Chain Analysis, Porter's Five Force Analysis, Drivers, Restraints, Vendor Profiles, Global Market Size, Forecasts & Analysis (2019-2027).

Healthy bone marrow is essentially soft, jellylike tissue located in the centers of bones and they produce blood cells at least in the range of billions per day. When disease or any random injury distresses the bone marrow to perturb its function effectively, a marrow or stem cell transplant could be the best treatment for some patients. Stem cells have the regenerative capacity, and they have a high range of potency depending on their location.

The global bone marrow transplant market is expected to benefit from the growing incidences of chronic diseases like the cases of leukemia, lymphomas, and different types of cancer & blood disorders. Also, the increasing numbers of allocated funds and grants for exploring the transplant procedures and regenerative medicines are driving the market growth. So considering these scenarios, Triton Market Research report on the global bone marrow transplant market depicts that the market will grow at a compound annual growth rate of 5.13% during the forecast period.

In autologous transplantation, stem cells or bone marrow to be transplanted are extracted from the patient’s body itself, and they are returned to the patient’s body at a later stage after the removal of the diseased cells via various conditioning. It is the most preferred choice for bone marrow transplantation due to better integration profile and subsequent fewer complications.

The prevalence of long term diseases like cancer and the resulting growing investments for their detection and diagnosis made by governmental as well as private funding bodies in the developed nation of the US and Canada are propelling the bone marrow transplant market in North America. Despite having a strong market base in the region, hurdles like the ethical issues, scarcity of bone marrow donor with poor genetic matches and the high cost for the surgery are restraining the growth and expansion of the market.

The global bone marrow transplant market has its leading companies like Roche Diagnostics Ltd., Stryker Corporation, Abbott Laboratories, Sanofi, Astellas Pharma Inc., Affymetrix, Inc. (acquired by Thermofisher), Diadexus Inc. (Acquired By Diazyme Laboratories), Agendiav, Illumina, Inc., Ambrilia Biopharma Inc., Qiagen N.V. and Agilent Technologies, Inc. are competing with each other for better market presence.